<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Patients with hyperleukocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> were graded according to the severity of symptoms possibly caused by <z:mp ids='MP_0008541'>leukostasis</z:mp> to evaluate the effectiveness of therapy and to test the relative contribution of blast type and count of blasts and promyelocytes in the development of <z:mp ids='MP_0008541'>leukostasis</z:mp> syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Ninety-five patients (59 male, 36 female, median age 52 yr) with hyperleukocytic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> [leukocytes above 50 x 10(9)/L, 48 <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), 31 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:mp ids='MP_0005481'>CML</z:mp>), 13 <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (ALL), three <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_501'>myelomonocytic leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>)] were grouped according to the presence or absence and severity of neurologic, pulmonary and other symptoms into four categories (no, possible, probable and highly probable <z:mp ids='MP_0008541'>leukostasis</z:mp> syndrome) </plain></SENT>
<SENT sid="2" pm="."><plain>Age, white blood count (WBC), <z:chebi fb="34" ids="35143">haemoglobin</z:chebi>, blast count and total of blasts plus promyelocytes of these groups were compared by Mann-Whitney U-test </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Patients with <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> M1/M2, <z:mp ids='MP_0005481'>CML</z:mp>) which scored as highly probable <z:mp ids='MP_0008541'>leukostasis</z:mp> showed significantly higher WBC (P = 0.011), lower <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (P = 0.004), higher peripheral blast counts (P = 0.004) and higher total of peripheral blasts plus promyelocytes (P &lt; 0.001) compared with the lower probability groups </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:mpath ids='MPATH_336'>leukaemia</z:mpath> involving the monocytic lineage (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> M4/M5, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) no significant differences were found in any of these factors between patients with highly probable <z:mp ids='MP_0008541'>leukostasis</z:mp> and the other patients </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: Our results show that a four-stage clinical grading scale is a valuable tool for analysing hyperleukocytic patient populations and evaluate the effectiveness of therapy more precisely </plain></SENT>
<SENT sid="6" pm="."><plain>We further demonstrate that the mechanisms of <z:mp ids='MP_0008541'>leukostasis</z:mp> are different in <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> as compared with <z:mpath ids='MPATH_336'>leukaemia</z:mpath> with involvement of the monocytic lineage </plain></SENT>
</text></document>